D. Knafelz

ORCID: 0000-0002-5343-2080
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Inflammatory Bowel Disease
  • Microscopic Colitis
  • Eosinophilic Esophagitis
  • Immunodeficiency and Autoimmune Disorders
  • Clinical Nutrition and Gastroenterology
  • Liver Diseases and Immunity
  • Adolescent and Pediatric Healthcare
  • Helicobacter pylori-related gastroenterology studies
  • Pediatric Hepatobiliary Diseases and Treatments
  • Intestinal Malrotation and Obstruction Disorders
  • Celiac Disease Research and Management
  • Metabolism and Genetic Disorders
  • Child Nutrition and Feeding Issues
  • Systemic Lupus Erythematosus Research
  • Childhood Cancer Survivors' Quality of Life
  • Diabetes and associated disorders
  • Pharmaceutical studies and practices
  • Autoimmune and Inflammatory Disorders
  • Gastrointestinal motility and disorders
  • Infant Health and Development
  • Food Allergy and Anaphylaxis Research
  • Electrolyte and hormonal disorders
  • Iron Metabolism and Disorders
  • Pancreatitis Pathology and Treatment
  • Pregnancy and Medication Impact

Bambino Gesù Children's Hospital
2016-2025

Istituti di Ricovero e Cura a Carattere Scientifico
2002-2025

Boston Children's Hospital
2005-2015

Unité de Nutrition Humaine
2012

Hospital Sant Joan de Déu Barcelona
2009

Great Ormond Street Hospital
1996-2009

University College London
1996-2009

University of Helsinki
2009

University of Rome Tor Vergata
1998

University of Sheffield
1997

The purpose was to assess in Italy the clinical features at diagnosis of inflammatory bowel disease (IBD) children.In 1996 an IBD register onset established on a national scale.Up end 2003, 1576 cases pediatric were recorded: 810 (52%) ulcerative colitis (UC), 635 (40%) Crohn's (CD), and 131 (8%) indeterminate (IC). In period 1996-2003 increase incidence from 0.89 1.39/10(5) inhabitants aged <18 years observed. more frequent among children between 6 12 (57%) but 20% patients had under age;...

10.1002/ibd.20470 article EN Inflammatory Bowel Diseases 2008-06-02

Background: Therapeutic drug monitoring (TDM) of infliximab (IFX) and adalimumab (ADL) mainly relies on the use enzyme-linked immunosorbent assays (ELISA). More recently, rapid have been developed validated to reduce turnaround time (TAT). Here, we compared IFX ADL concentrations measured with both ELISA a new fluorescence-based lateral flow immunoassay (AFIAS). Methods: In serum samples from pediatric patients, levels, total anti-IFX antibodies were using clinically kits (Immundiagnostik...

10.3390/pharmaceutics17040421 article EN cc-by Pharmaceutics 2025-03-26

Inflammatory bowel diseases (IBD) are characterized by periods of remission with recurrent episodes symptom exacerbation because acute intestinal inflammation, which is correctly evaluated endoscopy biopsy sampling. However, many surrogate markers including fecal calprotectin (FC), detected as potential predictors mucosal inflammation in IBD patients. The aim our study was to retrospectively assess the clinical efficacy assay determining histological relapses pediatric patients.We reviewed...

10.1002/ibd.20472 article EN Inflammatory Bowel Diseases 2008-04-08

Functional dyspepsia in childhood is commonly triggered by food allergen sensitised individuals. We investigated the topography of eosinophils and mast cells gastric antral lamina propria, interaction cell products with mucosal nerve fibres, changes muscle slow wave activity children atopy non-atopy-related functional dyspepsia.Open label study cow's milk challenge 10 atopic 6 nonatopic (ages 2-12 years) consecutively gastroscopy for dyspepsia. Simultaneous surface electrogastrography were...

10.1097/mpg.0b013e318186008e article EN Journal of Pediatric Gastroenterology and Nutrition 2008-10-01

Biologic therapies have changed the outcome of both adult and pediatric patients with Inflammatory Bowel Disease (IBD). In September 2013, first biosimilar infliximab was introduced into pharmaceutical market. 2015, a position paper on use biosimilars in IBD published by ESPGHAN Porto group. Since then, more data accumulated for adults children demonstrating are an effective safe alternative to originator. this updated statement, we summarize current evidence provide joint consensus...

10.1097/mpg.0000000000002141 article EN Journal of Pediatric Gastroenterology and Nutrition 2018-08-31

ABSTRACT Background: Inflammatory bowel disease (IBD) present in childhood 15% to 25% of cases. The aim therapy children is not only guarantee normal growth but also prevent relapse and maintain remission. Steroids are effective induce remission; however, resistance, dependency, irreversible side effects can develop. this study was determine whether treatment with repeated infusions autologous red blood cells (RBCs) loaded dexamethasone 21‐phosphate (Dex 21‐P) safe allows maintenance...

10.1097/mpg.0b013e3180320667 article EN Journal of Pediatric Gastroenterology and Nutrition 2007-03-19

Some reports highlight the potential application of fecal calprotectin as a direct biomarker intestinal inflammation and, therefore, support in choosing candidates for endoscopy. The value 100 μg/g was recently assumed best cutoff this assay. purpose study to assess diagnostic precision assay, compared histology, stool-screening inflammatory bowel disease (IBD) among group prospectively identified patients referred recurrent abdominal pain and altered habits.Between 1999 2007 we evaluated...

10.1002/ibd.21257 article EN Inflammatory Bowel Diseases 2010-03-22

Primary sclerosing cholangitis (PSC) is a chronic, fibroinflammatory, cholestatic liver disease of unknown etiopathogenesis, often associated with inflammatory bowel diseases. Recent evidence ascribes, together immunologic and environmental components, significant role to the intestinal microbiota or its molecules in PSC pathogenesis.

10.1093/ibd/izad203 article EN cc-by-nc Inflammatory Bowel Diseases 2023-09-11

Abstract Background Transition from pediatric to adult care of patients affected by Inflammatory Bowel Disease (IBD) is a critical step that needs specific and multidisciplinary involvement. The aim our study was evaluate the outcome transition process cohort IBD patients, exploring their readiness possible impact on quality life. Methods This observational followed transitioned care. carried-out through combined visits, jointly performed pediatrician gastroenterologist. Clinical data were...

10.1186/s13052-021-00977-x article EN cc-by ˜The œItalian Journal of Pediatrics/Italian journal of pediatrics 2021-01-28

Inflammatory bowel disease (IBD) has been associated with several polymorphisms in genes likely involved innate immune responses and integrity of epithelial mucosal barrier. A major role adult Crohn's (CD) defined for 3 the CARD15 gene, whereas variants SLC22A4, SLC22A5, DLG5 could have a minor contribution to IBD susceptibility.We analyzed panel 6 within these 227 Italian early-onset patients (134 CD, 93 ulcerative colitis [UC]; age at diagnosis <or=18 years) 166 unaffected control...

10.1097/01.mib.0000217338.23065.58 article EN Inflammatory Bowel Diseases 2006-05-01

Inflammatory bowel diseases [IBD] are chronic and pervasive conditions of the gastrointestinal tract with a rising incidence in paediatric young adult populations. Evidence suggests that psychological disorders might be associated relapse disease activity. This study aims to evaluate efficacy short-term psychodynamic psychotherapy [STPP] addition standard medical therapy [SMT] maintaining clinical remission adolescents adults [AYA] quiescent IBD, compared SMT alone.

10.1093/ecco-jcc/jjad145 article EN cc-by Journal of Crohn s and Colitis 2023-08-22

<h3>BACKGROUND</h3> The protozoan disease giardiasis can cause ocular complications, including "salt and pepper" retinal changes. <h3>METHODS</h3> Ophthalmic examinations were performed in 141 children (mean age 4.7 (SD 2.0) years) with active or past diagnosed on the basis of microscopic examination stool specimens duodenal secretions—53 newly untreated (group A), 50 had infections spite metronidazole therapy B), 38 been successfully treated, negative for 1–3 years C). 300 no evidence used...

10.1136/bjo.82.1.59 article EN British Journal of Ophthalmology 1998-01-01

ABSTRACT Objectives: The aim of this study was to evaluate the effectiveness and safety adalimumab (ADA) in children with ulcerative colitis (UC) previously treated infliximab (IFX). Methods: Retrospective including UC from a national registry who received ADA therapy. primary endpoint rate corticosteroid‐free remission at week 52. Secondary outcomes were sustained clinical remission, nonresponse, loss response weeks 12, 30, 52 mucosal healing side effects Results: Thirty‐two (median age 10...

10.1097/mpg.0000000000001883 article EN Journal of Pediatric Gastroenterology and Nutrition 2018-01-05
Coming Soon ...